This is in line with previous reports from Verma et al. [16,17], showing the potential of several AKR1C3 inhibitors to strongly synergise the cytotoxic effect of daunorubicin (>10-fold) on AML cell lines expressing AKR1C3. The gene discussed is AKR1C3; the disease is acute myeloid leukemia.